Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can extra support make telemedicine work better for diabetes?

NCT ID NCT06740435

Knowledge-focused Sponsor: University of Pittsburgh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether an enhanced telemedicine program is practical for adults with complex type 2 diabetes who use insulin and have other health conditions. Fifty participants will receive either standard telemedicine care or an enhanced version with extra pre-visit prep, in-visit support, and post-visit follow-up. The main goal is to see if the enhanced program is feasible and acceptable, not to prove it improves health outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Enhanced telemedicine program with pre-visit prep, in-visit support, and post-visit follow-up
What this could lead to
If successful, this could show that a more supportive telemedicine approach is practical and may improve care for people with complex diabetes.
What could go wrong
This is a small pilot study with only 50 participants, so results may not apply to everyone. It focuses on feasibility, not on proving health improvements.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * adults 18 years or older * Diagnosis of type 2 diabetes based on abbreviated ICD-10 code E11.X in medical record or self-report * HbA1c greater than or equal to 8% based on most recent value at time of recruitment * Patients must own or have access to a smart phone, tablet, or home computer with data or internet connection that allows access to video-based visits * Patient must use insulin * Patients must have \>2 comorbid chronic health conditions * Be able to provide informed consent * Reside in Pennsylvania Exclusion criteria: * Age over 80 based on date of birth in electronic medical record * Visit with an endocrinologist in the prior 1 years * Dementia, ESRD, malignancy based on abbreviated ICD-10 codes below in medical record or self-report of associated condition * Dementia: A81.0x, F01.5x, F02.8x, F03.9x, F10.27, F10.97, F13.27, F13.97, F18.97, F19.17, F19.27, F19.97, G30.x, G31.0x, G31.1, G31.83, G31.85 * Malignancy, except non-melanoma skin cancer: C00.x-C14.x, C15.x-C26.x, C3x.xx, C40.xx-C41.x, C43.x, C4A.xx, C45.x-C49.xx, C50.xxx, C51.x-C58, C60.x-C63.x, C64.x- C68.x, C69.xx-C72.x, C73-C76.x, C7A.xx, C80.xx-C96.x (except C90.x1, C91.x1, C92.x1, C93.x1, C94.x1, C95.x1) * ESRD N18.6 * Type 1, gestational, or other diabetes based on abbreviated ICD-10 codes below in medical record or self-report of associated condition * Type 1 diabetes: E10.X * Gestational diabetes: O24.X, E08.X * Other diabetes: E09.X, E13.2 * Pregnant or planning to become pregnant in next 6 months * Currently enrolled in another diabetes management intervention study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

Contacts and locations

Locations

  • University of Pittsburgh

    Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.